Takeda Pharmaceuticals North America Inc

Takeda Pharmaceuticals North America Inc. announced proposed new leadership for Takeda America Holdings Inc. (TAH), Takeda Pharmaceuticals North America Inc. (TPNA) and Takeda Global Research & Development Center Inc. (TGRD) following an earlier announcement related to Takeda's plans to conclude its joint venture in the United States, TAP Pharmaceutical Products Inc. (TAP). Effective at the close of the TAP transaction, Takeda Pharmaceuticals North America Inc. and Takeda Global Research & Development Center Inc. will report to Takeda America Holdings Inc. Alan MacKenzie, the current president of TAP and a former president of Takeda Pharmaceuticals North America Inc. has been named executive vice president of Takeda America Holdings. MacKenzie will also serve as CEO of Takeda Pharmaceuticals North America Inc. in addition to his role as executive vice president of Takeda America Holdings. Mark Booth, current president of Takeda Pharmaceuticals North America Inc., will continue to lead the company until the TAP transaction is closed and has agreed to continue on with the company for some period thereafter to support integration activities.